Marpai entered into Amendment No. 2 to its purchase agreement with AXA to adjust deferred purchase price terms related to the Maestro Health acquisition. From the amendment date through December 31, 2026, the company will pay AXA 35% of net offering proceeds only after Marpai receives $5 million in offering proceeds. The amendment also sets minimum annual payments of $0 in 2026, $1 million in 2027, $5 million in 2028, and $22.25 million in 2029, and restricts Marpai from incurring additional indebtedness beyond current levels. Management expects the changes to reduce near-term debt service and improve liquidity.
Agreement details:
- Agreement type: Amendment No. 2 to Membership Interest Purchase Agreement (payment terms modification)
- Counterparty: AXA
- Signed / Effective: Jul 16 2026 / Jul 16 2026
- Duration / Termination: Payment schedule through 2029; proceeds threshold through Dec 31 2026
- Reason: Reduce near-term debt service and enhance liquidity
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.